AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Restart Life Sciences Corp.

$0.05 -$0.04 (-42.82%)
OTC · 11 Sep 2026 20:00 UTC
Previous Close
$0.05
Day Range
$0.05 - $0.05
Year Range
$0.01$0.12
Market Cap
1.81M
AVG Volume
2.33K
Trailing/Forward PE
-1.83/-
PEG ratio
0.21
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (CAD)
05K10K15K2016201720182019202020212022202320242025
NMLSF Revenue (CAD) by year
PeriodRevenue (CAD)
20250
20240
20230
20220
20210
202011.47K
20197.19K
20180
20170
20160
Net Income (CAD)
-30M-20M-10M010M2016201720182019202020212022202320242025
NMLSF Net Income (CAD) by year
PeriodNet Income (CAD)
2025-1.39M
2024224.75K
2023-1.22M
2022-2.47M
2021-2.68M
2020-23.25M
2019-1.4M
2018-3.57M
2017-1.87M
2016-2.08M
Operating Income (CAD)
-10M010M20M2016201720182019202020212022202320242025
NMLSF Operating Income (CAD) by year
PeriodOperating Income (CAD)
2025-1.35M
2024-631.1K
2023-1.24M
2022-1.17M
2021-3.09M
202019.67M
2019-1.12M
2018-3.64M
2017-1.73M
2016-1.96M
EBITDA (CAD)
-4M-3M-2M-1M02016201720182019202020212022202320242025
NMLSF EBITDA (CAD) by year
PeriodEBITDA (CAD)
2025-1.34M
2024-656.2K
2023-1.24M
2022-1.93M
2021-2.93M
2020-1.79M
2019-1.21M
2018-3.55M
2017-1.8M
2016-1.96M
Cash Flows (CAD)
-2M-1.5M-1M-500K02016201720182019202020212022202320242025
NMLSF Cash Flows (CAD) by year
PeriodCash Flows (CAD)
2025-717.22K
2024-71.77K
2023-277.53K
2022-1.44M
2021-1.95M
2020-856.53K
2019-878.81K
2018-1.42M
2017-1.51M
2016-767.37K
EPS (CAD)
-6-4-2022016201720182019202020212022202320242025
NMLSF EPS (CAD) by year
PeriodEPS (CAD)
2025-0
20240.01
2023-0.08
2022-0.18
2021-0.25
2020-4.17
2019-0.44
2018-1.28
2017-0.83
2016-1.28
Expenses (CAD)
01M2M3M4MR&DSG&ACapex2016201720182019202020212022202320242025
NMLSF Expenses (CAD) by year
PeriodExpenses (CAD)
20251.06M
2024454.25K
20231.14M
20221.93M
20212.93M
20201.81M
20191.21M
20183.61M
20171.81M
20161.01M
Cash & Debt (CAD)
01M2M3MCashShort Term Debt2016201720182019202020212022202320242025
NMLSF Cash & Debt (CAD) by year
PeriodCash & Debt (CAD)
20251.65M
2024169.95K
20238.09K
2022266.52K
2021218.73K
20202.14M
2019847.42K
20182M
20171.21M
2016654.34K
Debt ratios
00.10.20.320182019202020212022202320242025
NMLSF Debt ratios by year
PeriodDebt ratios
20250.27
20240.01
20230
20220.03
20210.02
20200.26
20190.1
20180.25
Margins
0%10%20%30%20192020
NMLSF Margins by year
PeriodMargins
202015.07%
201922.61%
Return on Capital
-6000%-4000%-2000%0%2000%2016201720182019202020212022202320242025
NMLSF Return on Capital by year
PeriodReturn on Capital
2025-108.04%
2024-75.15%
2023151.05%
2022-5964.31%
2021-584.75%
2020-493.7%
2019-22.33%
2018-49.34%
2017-60.86%
2016-317.59%
Shares Outstanding
05B10B15B20B2016201720182019202020212022202320242025
NMLSF Shares Outstanding by year
PeriodShares Outstanding
202552.92M
202415.29B
202314.72B
202214.51B
202111.15B
20207.69B
20193.21B
20183.09B
20172.43B
20161.77B
Book Value Per Share (CAD)
-0.0100.010.020.032016201720182019202020212022202320242025
NMLSF Book Value Per Share (CAD) by year
PeriodBook Value Per Share (CAD)
20250.02
2024-0
2023-0
20220
20210
20200
20190
20180
20170
20160
Total Assets (CAD)
02M4M6M8M2016201720182019202020212022202320242025
NMLSF Total Assets (CAD) by year
PeriodTotal Assets (CAD)
20251.77M
2024190.4K
202331.06K
2022296.79K
2021881.16K
20205.09M
20196.58M
20187.55M
20173.22M
2016729.94K
PE Ratio
050000100000150000med 26581.72Jan 25Feb 25Mar 25Apr 25May 25May 25Jun 25
NMLSF PE Ratio by year
PeriodPE Ratio
Jun 254604.73
Jun 254305.57
Jun 254289.6
Jun 253965.96
May 254484
May 254984.68
May 255414.03
May 254358.21
May 254274.26
Apr 254332.46
Apr 253010.53
Apr 258014.24
Apr 254078.13
Mar 2570402.59
Mar 2575528.69
Mar 25134301.44
Mar 25109928.4
Feb 25128023.69
Feb 2595099.9
Feb 2581748.48
Feb 25116091.35
Jan 2545149.21
Jan 2587185.42
Jan 2548573.18
Jan 2563823.68
Jan 2572466.47
Free Cash Flow Yield
-60%-40%-20%0%med -0.1%Dec 24Apr 25Jul 25Oct 25Feb 26May 26Sep 26
NMLSF Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-14.62%
Sep 26-12.29%
Aug 26-14.42%
Aug 26-11.55%
Aug 26-10.68%
Aug 26-10.27%
Jul 26-11.23%
Jul 26-12.74%
Jul 26-10.48%
Jul 26-12.2%
Jul 26-20.11%
Jun 26-9.61%
Jun 26-13.19%
Jun 26-27.68%
Jun 26-46.08%
May 26-13.48%
May 26-19.7%
May 26-19.8%
May 26-19.9%
May 26-12.17%
Apr 26-7.98%
Apr 26-18.64%
Apr 26-17.49%
Apr 26-13.83%
Mar 26-0.11%
Mar 26-0.15%
Mar 26-0.15%
Mar 26-0.12%
Feb 26-0.12%
Feb 26-0.08%
Feb 26-0.1%
Feb 26-0.1%
Jan 26-0.1%
Jan 26-0.1%
Jan 26-0.09%
Jan 26-0.1%
Jan 26-0.09%
Dec 25-0.08%
Dec 25-0.08%
Dec 25-0.09%
Dec 25-0.11%
Nov 25-0.11%
Nov 25-0.12%
Nov 25-0.12%
Nov 25-0.15%
Oct 25-0.09%
Oct 25-0.09%
Oct 25-0.11%
Oct 25-0.1%
Oct 25-0.12%
Sep 25-0.14%
Sep 25-0.12%
Sep 25-0.11%
Sep 25-0.11%
Aug 25-0.11%
Aug 25-0.11%
Aug 25-0.11%
Aug 25-0.1%
Aug 25-0.1%
Jul 25-0.09%
Jul 25-0.11%
Jul 25-0.11%
Jul 25-0.15%
Jun 25-0.01%
Jun 25-0.01%
Jun 25-0.01%
Jun 25-0.01%
May 25-0.01%
May 25-0.01%
May 25-0.01%
May 25-0.01%
May 25-0.01%
Apr 25-0.01%
Apr 25-0.01%
Apr 25-0%
Apr 25-0.01%
Mar 25-0.01%
Mar 25-0.01%
Mar 25-0%
Mar 25-0%
Feb 25-0%
Feb 25-0.01%
Feb 25-0.01%
Feb 25-0%
Jan 25-0.01%
Jan 25-0.01%
Jan 25-0.01%
Jan 25-0.01%
Jan 25-0.01%
Dec 24-0.01%
Dec 24-0.01%
Dec 24-0.01%
Dec 24-0.01%
Nov 24-0.01%
Nov 24-0.01%
Nov 24-0.01%
Nov 24-0%
Nov 24-0.01%
Oct 24-0.01%
Oct 24-0.01%
Price to Sales
-200000002000000400000060000008000000med 702472.49Apr 21Aug 21Dec 21Jan 24Feb 25Sep 26
NMLSF Price to Sales by year
PeriodPrice to Sales
Sep 2628.6
Sep 2634.01
Aug 2629
Aug 2636.2
Aug 2639.14
Aug 2640.69
Jul 2637.22
Jul 2632.82
Jul 2639.9
Jul 2634.26
Jul 2620.79
Mar 25-37377.01
Mar 25-40098.47
Mar 25-71301.15
Mar 25-58361.41
Feb 25-67968.26
Feb 25-50488.9
Feb 25-43400.58
Feb 25-61633.34
Jan 25-23969.89
Jan 25-46287.08
Jan 25-25787.69
Jan 25-33884.23
Jan 25-38472.73
Mar 2498416.3
Mar 2499796.74
Mar 24103315.75
Mar 2499396.86
Mar 2477417.9
Feb 2491165.86
Feb 24111986.49
Feb 2494810.16
Feb 24107651.08
Jan 24102610.55
Jan 24108714.64
Jan 2493943.3
Jan 2495686.3
Dec 2389384.01
Mar 226915702.25
Mar 226258634.5
Mar 226517092.26
Mar 225594587.72
Feb 224591018.9
Feb 224403208.74
Feb 223719700.18
Feb 223505880.25
Jan 224130114.69
Jan 224223771.32
Jan 224271581.22
Jan 224339790.67
Dec 213932579.08
Dec 212402323.05
Dec 212761696.56
Dec 212723893.79
Dec 212962104.4
Nov 212919150.81
Nov 213492376.96
Nov 214032166.52
Nov 214517521.19
Oct 214405849.64
Oct 213064588.03
Oct 213062481.37
Oct 213654678.75
Oct 214163354.79
Sep 212202470.69
Sep 212193054.39
Sep 212178800.29
Sep 212473527.12
Aug 212235529.24
Aug 212768382.03
Aug 213407733.66
Aug 213387585.32
Jul 213395615.21
Jul 213542695.02
Jul 212817873.9
Jul 212564275.98
Jul 212323683.9
Jun 21633433.86
Jun 21568378.24
Jun 21594919.18
Jun 21497857.9
May 21633742.58
May 21653483.85
May 21599428.58
May 21878155.16
Apr 21831744.41
Apr 21878495.01
Apr 21837976.07
Apr 21940742.19
Apr 21967583.54
Mar 21473385.55
Mar 21564092.58
Mar 21602666.57
Mar 21575250.34
Feb 21683400.47
Feb 21792916.8
Feb 21815883.29
Feb 21747746.84
Jan 21721544.51
Jan 21863795.91
Price to Book
0100000200000300000med 3688.64Sep 22Dec 22Apr 23Aug 25Nov 25May 26Sep 26
NMLSF Price to Book by year
PeriodPrice to Book
Sep 262.49
Sep 262.97
Aug 262.53
Aug 263.16
Aug 263.41
Aug 263.55
Jul 263.24
Jul 262.86
Jul 263.48
Jul 262.99
Jul 261.81
Jun 265.8
Jun 264.23
Jun 262.01
Jun 261.21
May 264.13
May 262.83
May 262.81
May 262.8
May 264.58
Apr 266.98
Apr 262.99
Apr 263.19
Apr 264.03
Dec 256960.94
Dec 256214.3
Dec 255941.84
Dec 254953.42
Nov 254657.4
Nov 254231.15
Nov 254207.59
Nov 253387.49
Oct 255670.44
Oct 255624.92
Oct 254635.47
Oct 255251.09
Oct 254283.97
Sep 25699.88
Sep 25831.9
Sep 25867.53
Sep 25866.28
Aug 25911.95
Aug 25871.62
Aug 25871.22
Aug 25937.89
Aug 25980.29
Jul 251063.46
Jul 25931.87
Jul 25927.65
Jul 25675.17
Jun 23124441.51
Jun 23138950.84
Jun 23158675.55
Jun 23159239.64
May 23172003.94
May 23189461.56
May 23185769.56
May 23212652.4
Apr 23235005.73
Apr 23217167.24
Apr 23187497.35
Apr 23176157.47
Mar 23195687.74
Mar 239185.05
Mar 237904.45
Mar 237440.79
Mar 238072.07
Feb 238308.47
Feb 239518.55
Feb 238573.93
Feb 238633.97
Jan 2311669.46
Jan 2314257.65
Jan 2311992.19
Jan 2313428.68
Dec 2214434.6
Dec 2211285.99
Dec 229751.6
Dec 225957.66
Dec 223676.51
Nov 222983.98
Nov 223700.77
Nov 224173.09
Nov 223968.49
Oct 224649.22
Oct 224290.64
Oct 225518.35
Oct 225206.76
Sep 224782.97
Sep 222256.54
Sep 222811.95
Sep 222773.24
Sep 223013.27
Aug 222700.1
Aug 222783.65
Aug 222932.47
Aug 223197.34
Jul 223661.91
Jul 223893.92
Jul 223638.51
Restart Life Sciences Corp.
NMLSF
Stockpicker

Video analysis: NMLSF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: NMLSF

Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth

newsfilecorp.com · 3 Sep 2026

Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth

Vancouver, British Columbia--(Newsfile Corp. - September 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce its financial and operating results for the three and six months ended June 30, 2026. All financial figures are expressed in Canadian dollars ($) unless otherwise noted, are prepared in accordance with International Financial Reporting Standards (IFRS), and are unaudited.

Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations

newsfilecorp.com · 1 Sep 2026

Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations

Vancouver, British Columbia--(Newsfile Corp. - September 1, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its premium functional food brand, Holy Crap Foods Inc. ("Holy Crap"), has officially launched in the U.S. market through the Amazon USA platform. The initial U.S. rollout features two of the brand's top-performing super seed SKUs alongside a popular variety package.

Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line

newsfilecorp.com · 11 Aug 2026

Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line

Vancouver, British Columbia--(Newsfile Corp. - August 11, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce that its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"), has officially commenced commercial production of its highly anticipated new protein-focused product line. This marks a significant milestone in the Company's product development roadmap and underscores its core focus on revenue generation, scalable innovation, and expanding its "better-for-you" functional food portfolio.

Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors

newsfilecorp.com · 29 Jul 2026

Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors

Vancouver, British Columbia--(Newsfile Corp. - July 29, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a corporate update on its strategic growth initiatives as the Company actively pursues targeted merger and acquisition opportunities to further expand its presence in the health and wellness segments of the consumer packaged goods sector. Following the acquisition and successful operational rollout of wholly owned subsidiary Holy Crap Foods Inc. ("Holy Crap"), Restart Life is positioning itself as an active acquirer.

Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods

newsfilecorp.com · 21 Jul 2026

Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods

Vancouver, British Columbia--(Newsfile Corp. - July 21, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is providing a corporate update regarding its upcoming expansion into the United States, the launch of an updated AI-driven e-commerce platform, and pipeline developments for its wholly owned subsidiary, Holy Crap Foods Inc. ("Holy Crap"). The Company remains focused on scaling operations, driving revenue generation, and expanding its distribution reach.

Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks

newsfilecorp.com · 14 Jul 2026

Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks

Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a strategic operational update regarding its collaboration with the Richardson Centre for Food Technology and Research (RCFTR) at the University of Manitoba. Following the recent unveiling of its newly formulated product roadmap, targeted to capitalize on emerging consumer shopping patterns, the Company has successfully integrated the results from its collaboration with the RCFTR into its upcoming formulations.

Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap

newsfilecorp.com · 8 Jul 2026

Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update on its forward-looking product development and segment expansion roadmap for its wholly owned subsidiary, Holy Crap Foods Inc. Following the Company's recent disclosure of its preliminary June 2026 financial growth highlights, management is working to build upon this operational trajectory by systematically diversifying the Holy Crap brand into specialized consumer demographics. Following the successful completion of its market research and conceptual design phases, the Company has advanced into formulation testing for a new product line targeting the premium youth breakfast sector.

Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY

newsfilecorp.com · 2 Jul 2026

Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY

Vancouver, British Columbia--(Newsfile Corp. - July 2, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to report its preliminary, unaudited financial results for the month of June 2026 regarding its wholly owned subsidiary, Holy Crap Foods Inc., alongside an update on internal operational infrastructure and market expansion initiatives. Following the acquisition of Holy Crap Foods Inc. on February 27, 2026, the Company has focused on integrating operations, improving channel efficiencies, and expanding distribution networks.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.